ArrowMark Colorado Holdings LLC Decreases Stock Position in HealthEquity, Inc. (NASDAQ:HQY)

ArrowMark Colorado Holdings LLC lessened its position in HealthEquity, Inc. (NASDAQ:HQY) by 12.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 985,834 shares of the company’s stock after selling 135,035 shares during the quarter. ArrowMark Colorado Holdings LLC’s holdings in HealthEquity were worth $80,691,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in HQY. Price T Rowe Associates Inc. MD boosted its position in shares of HealthEquity by 7.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 51,384 shares of the company’s stock valued at $4,195,000 after buying an additional 3,365 shares during the period. GAMMA Investing LLC boosted its stake in shares of HealthEquity by 114.8% during the second quarter. GAMMA Investing LLC now owns 595 shares of the company’s stock valued at $51,000 after purchasing an additional 318 shares during the period. CWM LLC boosted its stake in shares of HealthEquity by 6.9% during the second quarter. CWM LLC now owns 3,958 shares of the company’s stock valued at $341,000 after purchasing an additional 255 shares during the period. SG Americas Securities LLC grew its holdings in shares of HealthEquity by 48.5% in the second quarter. SG Americas Securities LLC now owns 3,798 shares of the company’s stock worth $327,000 after purchasing an additional 1,241 shares during the last quarter. Finally, Sequoia Financial Advisors LLC bought a new stake in HealthEquity during the 2nd quarter valued at about $1,122,000. 99.55% of the stock is owned by hedge funds and other institutional investors.

HealthEquity Trading Down 0.9 %

Shares of NASDAQ:HQY opened at $101.54 on Monday. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51. HealthEquity, Inc. has a 52-week low of $62.10 and a 52-week high of $105.82. The stock has a market cap of $8.87 billion, a price-to-earnings ratio of 84.62, a PEG ratio of 1.59 and a beta of 0.52. The business has a 50-day moving average price of $90.16 and a 200-day moving average price of $82.85.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings data on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.50 by $0.16. The business had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. Equities analysts predict that HealthEquity, Inc. will post 2.27 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on HQY. Royal Bank of Canada restated an “outperform” rating and issued a $92.00 target price on shares of HealthEquity in a research note on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft increased their target price on shares of HealthEquity from $102.00 to $103.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. The Goldman Sachs Group started coverage on shares of HealthEquity in a research report on Friday, November 15th. They issued a “neutral” rating and a $108.00 price target for the company. Bank of America boosted their price target on HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $105.00 price objective on shares of HealthEquity in a research report on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $107.23.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Director Frank Corvino sold 1,247 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total value of $100,084.22. Following the sale, the director now directly owns 4,823 shares of the company’s stock, valued at approximately $387,093.98. This trade represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert W. Selander sold 8,250 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the transaction, the director now owns 54,719 shares in the company, valued at $4,540,582.62. This trade represents a 13.10 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,536 shares of company stock worth $884,517. Insiders own 2.20% of the company’s stock.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.